Antibody-Drug Conjugates (ADCs) are reaching a crescendo of interest from around the industry, with an increasing number of assets seen progressing rapidly through clinical stages. With this comes the pressing need to optimize all processes associated with their manufacture, whether this is conjugation, purification, scalability, or anything else. Join Merck, Amgen, Zymeworks, and our partner Cytiva, as we hear from some of the leading experts in cutting-edge companies in the space. They'll share their process development strategies to convert all the excitement into tangible ADC success!